PF-06647020 (PF-7020), an antibody-drug conjugate (ADC) targeting protein tyrosine kinase 7 (PTK7), in patients (pts) with advanced solid tumors: Results of a phase I dose escalation and expansion study.

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. 5565-5565 ◽  
Author(s):  
Jasgit C. Sachdev ◽  
Michael L. Maitland ◽  
Manish Sharma ◽  
Victor Moreno ◽  
Valentina Boni ◽  
...  
Keyword(s):  
Tyrosine Kinase ◽  
Phase I ◽  
Solid Tumors ◽  
Dose Escalation ◽  
Protein Tyrosine Kinase ◽  
Advanced Solid Tumors ◽  
Antibody Drug Conjugate ◽  
Drug Conjugate ◽  
Protein Tyrosine Kinase 7 ◽  
Antibody Drug

A phase I study of SAR566658, an anti CA6-antibody drug conjugate (ADC), in patients (Pts) with CA6-positive advanced solid tumors (STs)(NCT01156870).

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. 2511-2511 ◽  
Author(s):  
Carlos Alberto Gomez-Roca ◽  
Valentina Boni ◽  
Victor Moreno ◽  
John Charles Morris ◽  
Jean-Pierre Delord ◽  
...  
Keyword(s):  
Phase I ◽  
Solid Tumors ◽  
Phase I Study ◽  
Advanced Solid Tumors ◽  
Antibody Drug Conjugate ◽  
Drug Conjugate ◽  
Antibody Drug
Sign in / Sign up

Export Citation Format

Share Document